<DOC>
	<DOC>NCT01386944</DOC>
	<brief_summary>The objective is to assess the effect of Neupro® on the severity of Restless Leg Syndrome (RLS) symptoms and augmentation in patients with augmentation associated with previous oral dopaminergic therapy. In addition, the change in treatment regimen used when switching to Neupro® will be evaluated.</brief_summary>
	<brief_title>Effect on RLS Symptom Severity After Switching to Neupro® in Patients Who Previously Experienced Augmentation</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>The adult patient has a diagnosis of moderate to severe idiopathic Restless Leg Syndrome (RLS) The patient must be experiencing augmentation due to a prior dopaminergic treatment The decision to prescribe Neupro® has been made by the physician independently of his/her decision to enroll the patient in the study Patient is informed and given ample time and opportunity to think about his/her participation in the study and has given written informed data consent Patients diagnosed with secondary Restless Leg Syndrome (RLS) should not be enrolled in this observational study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro®</keyword>
	<keyword>Augmentation</keyword>
	<keyword>Restless Legs Syndrome</keyword>
	<keyword>Moderate to severe</keyword>
	<keyword>idiopathic</keyword>
	<keyword>adults</keyword>
</DOC>